Anlotinib is a potential antineoplastic and anti-angiogenic receptor tyrosine kinase (RTK) inhibitor. Anlotinib dramatically lowers the number of AN3CA cells in vitro, which are identified by high levels of mutated FGFR2 protein expression. After a 29-day treatment cycle, daily oral administration of anlotinib (5 mg/kg) resulted in a complete response in 55% of treated animals and in a reduced tumor volume and tumor weights of AN3CA tumors by 94% and 96%, respectively. While paclitaxel and carboplatin were unable to stop the growth of the tumor, their combination with anlotinib did not appear to have a better result than Anlotinib treatment alone.